Sanofi ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Margins
| Current |
|---|
Returns
10.9%ROE
6.2%ROA
Balance Sheet Health
Current Ratio1.09x
Cash & Equivalents$7.7B
Quality Metrics
Piotroski F-Score5 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPSFY2025: $6.37
Dividend
5.70%Yield3 yrsStreak+4.9%5-yr growth
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Dupixent | $15.7B | +25.2% | |
| Pharma launches | $3.9B | ||
| Vaccines | $7.9B | ||
| Other medicines | $16.1B |
Financials converted at 0.8513 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.